August 7, 2020

Dose Tapering Didn’t Affect QoL for Psoriasis Patients on Biologics

Is it possible to reduce dosages of biologics used to treat psoriasis without affecting efficacy? A recent study tested that theory with results published in JAMA Dermatology. Researchers note that biologics, which have revolutionized the treatment of psoriasis, are given in a fixed dose. The Dutch investigators questioned, however, whether lower dosages might be possible. Read more.


Which Patients Are Most Likely to Die From COVID-19?

Patients diagnosed with COVID-19 are increasingly confused about when they should tough out symptoms at home and when they need stepped-up care in a hospital. As a result, they are seeking guidance from pharmacists and other healthcare professionals. Knowing which patients are most likely to have the most serious outcome from novel coronavirus—death—can help ensure that those most at risk get the level of care they need. Read more.

Azithromycin Linked to Higher Risk of Cardiovascular Death 

In a recently published cohort study, researchers sought to estimate the relative and absolute risks of cardiovascular and sudden cardiac death after outpatient use of azithromycin compared with amoxicillin. This retrospective cohort study included two large, diverse, community-based integrated care delivery systems with comprehensive capture of encounters and prescriptions from 1998 to 2014. Read more.


Statins Continue to Have CV, Mortality Benefit in Patients Aged 75 Years and Older

A recent trend has been to deprescribe preventive medication for older patients. A new study suggests, however, that those actions should be taken with some caution. Researchers from Brigham and Women’s Hospital and the Veterans Affairs Boston Healthcare System looked at the benefits of statins in veterans aged 75 years and older, and their results raise questions about the benefits of discontinuation. Read more.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -